Evidence map›Paper›PMID 20962620›Full record

ArticleThe American journal of surgical pathology2010

IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas.

Alexandra Valera, Olga Balagué, Luis Colomo, Antonio Martínez, Jan Delabie, Lekidelu Taddesse-Heath, Elaine S Jaffe, Elías Campo

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of surgical pathology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed, 2 pooled it
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

109 citing papers in PubMed, 2 syntheses or guidelines pooled it, 274 citations in OpenAlex.

  1. Pooled it
  2. CD20-negative diffuse large B cell lymphoma: a comprehensive analysis of 695 cases.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Pooled it
  3. Article
  4. Article
  5. Inflammatory gene expression profile of oral plasmablastic lymphoma.Virchows Archiv : an international journal of pathology · 2026
    Article
  6. Selective MYC 5' amplification in postirradiation/lymphedema-associated angiosarcoma.Virchows Archiv : an international journal of pathology · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

49 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Alexandra ValeraHematopathology Section, Laboratory of Pathology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Olga Balagué
Luis Colomo
Antonio Martínez
Jan Delabie
Lekidelu Taddesse-Heath
Elaine S Jaffe
Elías Campo
Universitat de Barcelona · ESHoward University Hospital · USNational Institutes of Health · USUniversity of Oslo · NO

Funding

Lymphoma Disease Discovery and DefintionZIASC000550 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI JAFFE, ELAINE · 2009 to 2025
$16.9M
Lymphoma Disease Discovery and DefintionZ01SC000550 · SC · DIVISION OF CLINICAL SCIENCES - NCI · PI JAFFE, ELAINE · 1996 to 2008
$2.3M
Intramural NIH HHS Z01 SC000550
6 · The paper itself

Abstract

Plasmablastic lymphoma (PBL) is an aggressive lymphoma characterized by a terminally differentiated B-cell phenotype that usually occurs in the immunocompromised or elderly patients. Although the clinical and pathologic characteristics of these tumors have been defined, the genetic alterations involved in their pathogenesis are not well known. In this study, we have investigated the chromosomal alterations of MYC, BCL2, BCL6, MALT1, PAX5, and IGH loci using fluorescence in situ hybridization in 42 PBL and 3 extracavitary primary effusion lymphomas. MYC rearrangements were identified in 20 of 41 (49%) PBL and the immunoglobulin (IG) genes were the partners in most tumors. MYC rearrangements were more common in Epstein-Barr virus (EBV)-positive (14 of 19, 74%) than EBV-negative (9 of 21, 43%) tumors (P<0.05). No rearrangements of BCL2, BCL6, MALT1, or PAX5 were detected in any PBL but gains of these loci were observed in 31% to 41% of the cases examined. Twelve of the 40 PBL in which 3 or more loci could be investigated had multiple simultaneous gains in 3 or more loci. No differences in the survival of the patients according to MYC were observed but the 4 patients with the longest survival (>50 mo) had no or low number of gains (<3). No rearrangements of any of these loci were seen in the primary effusion lymphomas. In conclusion, PBL are genetically characterized by frequent IG/MYC translocations and gains in multiple chromosomal loci. The oncogenic activation of MYC in these lymphomas may be an important pathogenetic element associated with EBV infection.

Indexed as

Cytogenetic AnalysisGene RearrangementGenes, ImmunoglobulinTranslocation, GeneticAdultAgedAged, 80 and overChildFemaleHerpesvirus 4, HumanHumansImmunohistochemistryImmunophenotypingIn Situ Hybridization, FluorescenceLymphoma, Large B-Cell, DiffuseMaleMYC protein, humanProto-Oncogene Proteins c-myc

Identifiers

PMID20962620
PMCPMC2982261
OpenAlexW1995926405

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.